Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Adiposopathy
Clinical practice statement
Nonalcoholic fatty liver disease
Obesity
Pre-obesity
Journal
Obesity Pillars (Online)
ISSN: 2667-3681
Titre abrégé: Obes Pillars
Pays: United States
ID NLM: 9918697364706676
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
02
07
2022
accepted:
02
07
2022
medline:
8
7
2022
pubmed:
8
7
2022
entrez:
22
11
2023
Statut:
epublish
Résumé
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of nonalcoholic fatty liver disease (NAFLD), potential progression to nonalcoholic steatohepatitis (NASH), and their application to obesity. The scientific information for this CPS is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership. Topics of this CPS include the prevalence of NAFLD and NASH, the prevalence of NAFLD and NASH among patients with obesity, as well as NAFLD and NASH definitions, diagnosis, imaging, pathophysiology, differential diagnosis, role of high fructose corn syrup and other simple sugars, and treatment (e.g., nutrition, physical activity, medications). This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) regarding NAFLD and obesity is one of a series of OMA CPSs designed to assist clinicians in the care of patients with the disease of obesity. Patients with obesity are at increased risk for NAFLD and NASH. Patients may benefit when clinicians who manage obesity understand the etiology, diagnosis, and optimal treatment of NAFLD with a goal to prevent NASH.
Sections du résumé
Background
UNASSIGNED
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of nonalcoholic fatty liver disease (NAFLD), potential progression to nonalcoholic steatohepatitis (NASH), and their application to obesity.
Methods
UNASSIGNED
The scientific information for this CPS is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership.
Results
UNASSIGNED
Topics of this CPS include the prevalence of NAFLD and NASH, the prevalence of NAFLD and NASH among patients with obesity, as well as NAFLD and NASH definitions, diagnosis, imaging, pathophysiology, differential diagnosis, role of high fructose corn syrup and other simple sugars, and treatment (e.g., nutrition, physical activity, medications).
Conclusions
UNASSIGNED
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) regarding NAFLD and obesity is one of a series of OMA CPSs designed to assist clinicians in the care of patients with the disease of obesity. Patients with obesity are at increased risk for NAFLD and NASH. Patients may benefit when clinicians who manage obesity understand the etiology, diagnosis, and optimal treatment of NAFLD with a goal to prevent NASH.
Identifiants
pubmed: 37990727
doi: 10.1016/j.obpill.2022.100027
pii: S2667-3681(22)00018-3
pmc: PMC10661876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100027Informations de copyright
© 2022 The Authors.
Références
Dig Dis. 2016;34 Suppl 1:19-26
pubmed: 27547937
Am J Gastroenterol. 2021 Sep 1;116(9):1833-1841
pubmed: 34160377
Int J Mol Sci. 2020 Aug 18;21(16):
pubmed: 32824723
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Sci Rep. 2018 Mar 16;8(1):4718
pubmed: 29549269
BMC Gastroenterol. 2020 Jan 14;20(1):10
pubmed: 31937252
Nutrients. 2017 Sep 16;9(9):
pubmed: 28926951
J Hepatol. 2018 Feb;68(2):268-279
pubmed: 29122391
Clin Liver Dis. 2004 Nov;8(4):861-79, ix
pubmed: 15464659
J Hepatol. 2018 May;68(5):1063-1075
pubmed: 29408694
Iran J Public Health. 2017 Aug;46(8):1007-1017
pubmed: 28894701
J Clin Lipidol. 2013 Jul-Aug;7(4):304-83
pubmed: 23890517
Liver Int. 2020 Jun;40(6):1254-1261
pubmed: 32301554
Int J Mol Sci. 2016 May 20;17(5):
pubmed: 27213358
J Clin Med. 2021 May 29;10(11):
pubmed: 34072480
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Radiology. 2015 Feb;274(2):416-25
pubmed: 25247408
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185
pubmed: 35418240
Liver Int. 2017 Jan;37(1):121-131
pubmed: 26991726
Mol Nutr Food Res. 2022 Apr;66(7):e2101115
pubmed: 35124887
Metabolism. 2016 Aug;65(8):1183-95
pubmed: 27301803
Scand J Gastroenterol. 2014 Nov;49(11):1343-8
pubmed: 25259621
Am J Clin Nutr. 2016 Jun;103(6):1453-7
pubmed: 27099245
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334
pubmed: 28107283
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Liver Int. 2020 Feb;40 Suppl 1:102-108
pubmed: 32077594
BMJ. 2018 Nov 21;363:k4644
pubmed: 30463844
Curr Vasc Pharmacol. 2018;16(3):269-275
pubmed: 28676018
Diabetologia. 2011 Feb;54(2):271-9
pubmed: 20978741
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
J Hepatol. 2016 Dec;65(6):1245-1257
pubmed: 27486010
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
Nutrients. 2015 Nov 13;7(11):9453-74
pubmed: 26580649
Dig Dis. 2010;28(1):155-61
pubmed: 20460905
Curr Hepatol Rep. 2014 Jun 1;13(2):119-129
pubmed: 25045618
Am J Prev Cardiol. 2021 Mar 27;6:100176
pubmed: 34327499
J Clin Lipidol. 2016 Jan-Feb;10(1):33-57
pubmed: 26892120
Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398
pubmed: 30902670
Gastroenterol Hepatol (N Y). 2019 Jul;15(7):357-365
pubmed: 31391806
Therap Adv Gastroenterol. 2012 May;5(3):199-207
pubmed: 22570680
Open Forum Infect Dis. 2019 Mar 01;6(4):ofz099
pubmed: 30968054
Clin Mol Hepatol. 2017 Dec;23(4):290-301
pubmed: 28994271
Hepatology. 2018 Aug;68(2):763-772
pubmed: 29356032
Crit Rev Clin Lab Sci. 2016;53(1):52-67
pubmed: 26376619
Front Pediatr. 2022 Jan 11;9:784221
pubmed: 35087774
N Engl J Med. 2021 Mar 25;384(12):1113-1124
pubmed: 33185364
Diseases. 2018 Oct 03;6(4):
pubmed: 30282916
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Diabetol Metab Syndr. 2020 Jul 14;12:60
pubmed: 32684985
Acta Radiol. 2016 Mar;57(3):271-8
pubmed: 25855666
Diabetes Care. 2018 Aug;41(8):1732-1739
pubmed: 29844096
Expert Rev Clin Pharmacol. 2021 Mar;14(3):333-340
pubmed: 33535836
Ochsner J. 2002 Spring;4(2):92-7
pubmed: 22822324
Nutrients. 2019 May 02;11(5):
pubmed: 31052523
Surg Obes Relat Dis. 2016 Mar-Apr;12(3):468-495
pubmed: 27050404
Postgrad Med J. 2019 Nov;95(1129):601-611
pubmed: 31434683
J Hepatol. 2021 Oct;75(4):770-785
pubmed: 33991635
J Clin Invest. 2006 Jun;116(6):1494-505
pubmed: 16691291
Curr Atheroscler Rep. 2014 May;16(5):409
pubmed: 24659222
Hepat Res Treat. 2011;2011:972759
pubmed: 22254137
Diabetes Metab Syndr Obes. 2019 May 27;12:821-826
pubmed: 31213868
Curr Obes Rep. 2019 Sep;8(3):220-228
pubmed: 30945129
Gastroenterol Hepatol (N Y). 2015 Mar;11(3):167-75
pubmed: 27099587
Alcohol Alcohol. 2004 Jul-Aug;39(4):336-9
pubmed: 15208167
World J Gastroenterol. 2018 Aug 14;24(30):3361-3373
pubmed: 30122876
Hepatol Commun. 2022 Apr;6(4):765-779
pubmed: 34970870
Gene Expr. 2018 May 18;18(2):89-101
pubmed: 29212576
Sci Rep. 2018 May 17;8(1):7759
pubmed: 29773823
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276
pubmed: 29307986
Nutrients. 2016 Oct 14;8(10):
pubmed: 27754404
Endocr Pract. 2022 May;28(5):528-562
pubmed: 35569886
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):422-424
pubmed: 34015351
Dig Dis Sci. 2022 Feb;67(2):408-422
pubmed: 34981313
Nutrition. 2019 May;61:119-124
pubmed: 30710884
Eur J Clin Nutr. 1992 Oct;46 Suppl 2:S91-101
pubmed: 1330533